Former Merck and Johnson & Johnson Executives Join SomnoMed Board

Share Article

SomnoMed Limited announces changes to its board of directors, which will take effect on 30th September 2011.

SomnoMed Limited announces changes to its board of directors, which will take effect on 30th September 2011.

Paul Hopper will be resigning as a director of SomnoMed Limited. Mr. Hopper joined the board of SomnoMed in July 2007. He is currently a Managing Director of investment bankers Capello Group in Los Angeles and serves on a number of boards of public companies in the biotech and medical device area.

Chairman of SomnoMed Limited Dr. Peter Neustadt said, “Paul Hopper has expressed his wish to concentrate more on his activities as an investment banker at Capello in the US. On behalf of our board and shareholders I would like to thank Paul for serving four years on our board. Paul’s experience in the biotech and medical area was very beneficial and assisted in the development of SomnoMed’s business during his term as a director.”

Lee Ausburn and Robert Scherini will be joining the SomnoMed Board. Both are well-known names in the medical device and pharmaceutical industry, representing a combined experience of over fifty years in the corporate medical world.

“It gives me great pleasure to welcome Lee and Robert to the board of SomnoMed Limited. It is a great achievement for our company to attract two personalities with such tremendous national and international experience in the medical arena to join us as directors of our company. I am confident that both will be able to contribute greatly to the future global development of our company,” said Dr. Neustadt.

Lee Ausburn and Robert Scherini will join the Board on 30th September 2011 and will be nominated for reelection at the next AGM on 21st November 2011.

Background on New Directors

Lee Ausburn M.Pharm., B.Pharm., Dip.Hosp.Pharm. (University of Sydney)

Lee has had a long career in the health industry, beginning as a pharmacist before joining Merck and Co. Inc., a global pharmaceutical company. During this period, she progressed through a range of roles, beginning in marketing before becoming responsible for reimbursement and pricing of Merck products in Australia.

In 1998 she moved into a regional role and was ultimately Vice President, Asia Merck & Co. Inc. responsible for the general management and strong growth of Merck organisations and their products across Asia reporting directly to the executive responsible for the geographic area in the US. During this time Lee built businesses in a number of countries, often from the very beginning, planned and launched new products, liaised with regulatory authorities and government agencies and built and supervised management teams responsible for building Merck’s business in that part of the world.

After leaving Merck in 2008, she has taken on a number of non-executive director roles. She is a non-executive director of Australian Pharmaceutical Industries (API) Ltd, which distributes pharmaceuticals to pharmacies across Australia. API also has retail pharmacy operations through Priceline stores.

In addition she is a member of two NSW government boards which are responsible for the implementation of the Garling recommendations to improve the quality of care in NSW hospitals- the Clinical Excellence Commission and the Agency for Clinical Innovation.

Robert Scherini

Rob is a past Managing Director for Johnson & Johnson Medical Australia/NZ and has held senior management positions both locally and internationally. He was posted for a number of years in J&J international headquarter in Brussels before returning to Australia where he was directly responsible for J&J’s medical device business in the APAC region. He has a strong track record of growing businesses and brings to the Board a wealth of experience in Sales & Marketing, Business Development, Finance, Operations and Supply, Legal, Human Resources and Information Technology.

Rob has a bachelor degree in Business and is a Certified Practising Accountant (CPA). He was a Member of the Board of the Medical Technology Association of Australia (MTAA) for nine years. He has been a strong advocate of Human Resources Strategy and was recognised as Best HR Champion at the 2004 Australian HR Awards. In 2007 was awarded a Rotary International Fellowship for his assistance to the community.

More recently Rob has devoted his time to consulting and mentoring. He is a senior partner of a healthcare consultancy focused on Asia Pacific and a member of the Board of a large privately owned medical device company. Rob is also a member of the Executive Advisory Council of Nursing & Midwifery at the University of Technology, Sydney (UTS).

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Anthony White
SomnoMed
1(888) 447-6673
Email >
Visit website